Christchurch mutation prevents DNA breaks in dopamine neurons
The investigation was led by Dr. Vivek Unni and postdoctoral fellow Dr. Carlos Soto-Faguas at the OHSU School of Medicine. The team focused on the APOE Christchurch genetic variant, previously studied primarily in the context of Alzheimer's disease resistance. Parkinson's disease and Lewy body dementia are characterized by the abnormal accumulation of misfolded alpha-synuclein protein aggregates inside dopamine-producing neurons. These toxic clusters disrupt cellular function and trigger progressive cell death, and cell loss drives symptoms. Lewy body dementia represents the second most common form of degenerative dementia behind Alzheimer's.
In experimental cellular and animal models, researchers found that the Christchurch mutation prevents toxic protein aggregates from inducing lethal double-strand DNA breaks. Neurons carrying the variant maintained normal survival rates despite protein accumulation, and DNA damage was averted. The finding suggests that blocking the downstream toxic signaling pathway can preserve neuron viability even when misfolded proteins remain present. Current Parkinson's treatments primarily replenish dopamine levels or alleviate motor tremors without halting the underlying death of brain cells.
Dr. Soto-Faguas noted that developing synthetic therapeutics or viral gene delivery systems that replicate the variant's protective effect could slow or halt neurodegenerative decline in high-risk patients. The OHSU team plans to expand preclinical trials to determine the exact molecular binding partners through which the Christchurch variant shields neuronal DNA. Collaborative studies with pharmaceutical partners are currently in discussion.
The research received financial backing from the Oregon Alzheimer's Disease Research Center, the Parkinson Center, the American Parkinson Disease Association, and Stop Alzheimer's Now. Co-authors included Abigail O'Niel and Dr. Randall Woltjer. Potential therapeutic avenues include engineered monoclonal antibodies that block specific proteoglycan binding epitopes, small-molecule allosteric modulators that replicate the Christchurch conformational change, and adeno-associated virus (AAV) gene delivery vectors.
